| Texto completo | |
| Autor(es): |
Bomfim, Gisele Facholi
;
Assis Cau, Stefany Bruno
;
Bruno, Alexandre Santos
;
Fedoce, Aline Garcia
;
Carneiro, Fernando S.
Número total de Autores: 5
|
| Tipo de documento: | Artigo Científico |
| Fonte: | British Journal of Pharmacology; v. 176, n. 12, p. 21-pg., 2019-06-01. |
| Resumo | |
Arterial hypertension represents a serious public health problem, being a major cause of morbidity and mortality worldwide. The availability of many antihypertensive therapeutic strategies still fails to adequately treat around 20% of hypertensive patients, who are considered resistant to conventional treatment. In the pathogenesis of hypertension, immune system mechanisms are activated and both the innate and adaptive immune responses play a crucial role. However, what, when and how the immune system is triggered during hypertension development is still largely undefined. In this context, this review highlights scientific advances in the manipulation of the immune system in order to attenuate hypertension and end-organ damage. Here, we discuss the potential use of immunosuppressants and immunomodulators as pharmacological tools to control the activation of the immune system, by non-specific and specific mechanisms, to treat hypertension and improve end-organ damage. Nevertheless, more clinical trials should be performed with these drugs to establish their therapeutic efficacy, safety and risk-benefit ratio in hypertensive conditions. Linked Articles This article is part of a themed section on Immune Targets in Hypertension. To view the other articles in this section visit (AU) | |
| Processo FAPESP: | 16/11988-5 - Contribuição do NLRP3 para o efeito pró-inflamatório da ET-1 em células de músculo liso do corpo cavernoso: relevância na função erétil. |
| Beneficiário: | Fernando Silva Carneiro |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |